Main content

    Breast Cancer Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Active Trials

    Title: A Multicenter, Multinational, Phase II Study to Evaluate Pertuzumab in Combination With Trastuzumab and Standard Neoadjuvant Anthracycline-based Chemotherapy in Patients With HER2-Positive, Locally Advanced, Inflammatory, or Early-Stage Breast Cancer
    Description: This study study is designed to evaluate the safety and efficacy of Perjeta in combination with Herceptin and anthra cycline-based chemotherapy as neoadjuvant treatment in patients with HER2-based locally advanced, inflammatory, or early-stage breast cancer
    Investigator: Wei Wang, MD
    Eligibility: Male and female subjects, 18 y/o and older, with locally advanced, inflammatory, or early-stage, unilateral, and histologically confirmed invasive breast cancer. Patients with inflammatory breast cancer must be able to have a core needle biopsy
    Status: Active and open to enrollment
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study Genentech WO29217

    Title: A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients With Metastatic Breast Cancer
    Description: This randomized phase III trial is studying early surgery to see how well it works compared to standard palliative therapy in treating patients with stage IV breast cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Male and female subjects, 18 y/o and older, who have a diagnosis of intact primary (not recurrent) invasive carcinoma of the breast
    Status: Please contact site for study status
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study ECOG E2108

    A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less
    Description: RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Female subjects, 18 y/o and older, who have a histologically confirmed diagnosis of node positive (1-3 nodes) invasive breast carcinoma with positive estrogen and/or progesterone receptor status, and negative HER-2 status; estrogen and progesterone receptor positivity
    Status: Please contact site for study status
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study SWOG S1007

    Title: A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women With Early Stage Breast Cancer
    Description: This randomized phase III trial studies how well duloxetine hydrochloride works compared to a placebo in treating muscle, bone, and joint pain in patients with early-stage breast cancer receiving hormone therapy
    Investigator: NCI - National Cancer Institute
    Eligibility: Female subjects, 18 y/o and older, who have histologically confirmed estrogen receptor (ER)- and/or progesterone receptor (PgR)-positive invasive carcinoma of the breast with no evidence of metastatic disease (M0)
    Status: Please contact site for study status
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study SWOG S1202

    Title: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
    Description: This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Male and female subjects, 18 y/o and older, who have a histologically confirmed diagnosis of invasive breast carcinoma with positive estrogen (ER)- and/or progesterone-receptor (PR) status, and negative human epidermal growth factor receptor (HER)2, for whom standard adjuvant endocrine therapy is planned
    Status: Please contact site for study status
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study SWOG S1207

    Title: A Randomized Phase 3 Clinical Trial Evaluating Post-Mastectomy Chestwall & Regional Nodal XRT & Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemo Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemo
    Description: Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
    Investigator: NCI - National Cancer Institute
    Eligibility: Female subjects, 18 y/o and older, who have clinically T1-3, N1 breast cancer at the time of diagnosis (before neoadjuvant therapy) and who have had pathologic confirmation of axillary nodal involvement at presentation (before neoadjuvant therapy)
    Status: Please contact site for study status
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study NSABP B-51

    Title: A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
    Description: Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 years and older, who have a histologically confirmed non-metastatic primary triple negative invasive adenocarcinoma of the breast.
    Status: Please contact site for study status
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study NSABP B-55

    Title: Randomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
    Description: Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
    Investigator: NCI - National Cancer Institute
    Eligibility: Female subjects, 18 y/o and older, who have undergone a total mastectomy or breast-conserving surgery for primary breast cancer +/-chemotherapy and +/-radiotherapy
    Status: Please contact site for study status
    Contact: Brenda Eng, 415-600-1775, Email: EngB@cpmcri.org about Study Alliance A221102

    Title: Phase II Randomized Study of Whole Brain Radiotherapy in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer: A Collaborative Study of NRG Oncology and KROG
    Description: This randomized phase II trial studies how well whole-brain radiation therapy (WBRT) with or without lapatinib ditosylate works in treating patients with breast cancer that has too many of a protein called human epidermal growth factor receptor 2 (HER2) on its cells and has spread to the brain
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, with pathologically (histologically or cytologically) proven diagnosis of invasive breast cancer
    Status: Please contact site for study status
    Contact: Madeline Decker, 415-600-3613, Email: EngB@cpmcri.org about Study RTOG 1119

    Title: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
    Description: This randomized phase III trial studies axillary lymph node dissection to see how well it works compared to axillary radiation therapy in treating patients with node-positive breast cancer treated with neoadjuvant chemotherapy followed by surgery
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, with a clinical stage T1-3 N1 M0 breast cancer at diagnosis (prior to the start of neoadjuvant chemotherapy) by American Joint Committee on Cancer (AJCC) staging 7th edition
    Status: Please contact site for study status
    Contact: Madeline Decker, 415-600-3613, Email: EngB@cpmcri.org about Study A011201

    Title: A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer
    Description: This is a randomized, double-blind, placebo controlled clinical trial comparing the overall survival of women with advanced or metastatic HER2-negative breast cancer who receive treatment with capecitabine in combination with ruxolitinib versus those who receive treatment with capecitabine alone
    Investigator: Ari Baron, MD
    Eligibility: Female subjects, 18 y/o and older, who have a histologically or cytologically confirmed HER2-negative adenocarcinoma of the breast
    Status: Active and open to enrollment
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study Incyte 268

    Title: A Phase II, Single Arm Study of the Use of Steroid-based Mouthwash to Prevent Stomatitis in Postmenopausal Women With Advanced or Metastatic Hormone Receptor Positive Breast Cancer Being Treated With Everolimus Plus Exemestane
    Description: Open-label, Phase II study of Stomatitis prevention with a steroid-based mouthwash in Post-menopausal women with ER+, HER2- Metastatic or Locally Advanced Breast Cancer
    Investigator: Wei Wang, MD
    Eligibility: Female subjects, 18 y/o and older, who have metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy
    Status: Active and open to enrollment
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study Novartis STOPP

    Title: Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
    Description: A Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine On Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim
    Investigator (Santa Rosa): Peter Brett, MD
    Eligibility: Female subjects, 18 y/o and older, with newly diagnosed, not previously treated with chemotherapy, stage I-III breast cancer
    Status: Active and open to enrollment
    Contact (Santa Rosa): Christina DeVisser, 707-576-4739, Email: DevissC@cpmcri.org about Study Amgen 20110147

    Title: A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer
    Description: This study is to determine whether treatment with a PI3K inhibitor plus letrozole leads to an increase in pathologic response compared to treatment with placebo plus letrozole in patients with Breast cancer
    Investigator (Santa Rosa): Eric Dean, MD
    Eligibility: Postmenopausal subjects, 18 y/o and older, with a histologically and/or cytologically confirmed diagnosis of breast cancer
    Status: Active and open to enrollment
    Contact (Santa Rosa): Christina DeVisser, 707-576-4739, Email: DevissC@cpmcri.org about Study Novartis CBYL719A2201

    • updated March 2015

    Back to top